Advancing Rentosertib: An AI-Discovered TNIK Inhibitor Targeting IPF in Global Phase 2 & 3 Trials
- Detailing the discovery and development of Rentosertib (INS018_055), a first-in-class small molecule TNIK inhibitor identified through end-to-end generative AI
- Overview of clinical progression: positive safety and efficacy signals from a completed Phase 2a trial, with Phase 2b in the US and a Phase 3 trial underway in China
- Reflections on the integration of AI in early discovery and translational development, and navigating multinational clinical trial strategies for IPF